Brivudine
Brivudine structure
|
Common Name | Brivudine | ||
|---|---|---|---|---|
| CAS Number | 69304-47-8 | Molecular Weight | 333.135 | |
| Density | 1.9±0.1 g/cm3 | Boiling Point | 382.9ºC at 760 mmHg | |
| Molecular Formula | C11H13BrN2O5 | Melting Point | 165ºC | |
| MSDS | USA | Flash Point | 185.4ºC | |
Use of BrivudineBrivudine is a thymidine analogue with antiviral activity, indicated for the early treatment of acute herpes zoster. |
| Name | Brivudine |
|---|---|
| Synonym | More Synonyms |
| Description | Brivudine is a thymidine analogue with antiviral activity, indicated for the early treatment of acute herpes zoster. |
|---|---|
| Related Catalog | |
| In Vitro | Brivudine is an analog of thymidine, and is incorporated into the viral DNA. It blocks the action of DNA polymerases, thus inhibiting viral replication. It has a stronger antiviral effect against the varicella-zoster virus compared with reference compounds such as aciclovir or penciclovir[1]. It has high, selective activity against varicella zoster virus (VZV), inhibiting VZV replication, possibly through competitive inhibition of viral DNA polymerase, or by acting as an alternative substrate to deoxythymidine triphosphate, causing viral DNA strand breakage[2]. |
| In Vivo | At a dose of 125 mg once daily, brivudine has proved to be superior to aciclovir with respect to reducing the period of new blister production, and has shortened the duration of post-herpetic neuralgia[1]. |
| References |
[2]. Keam SJ, et al. Brivudin (bromovinyl deoxyuridine). Drugs. 2004;64(18):2091-7; discussion 2098-9. |
| Density | 1.9±0.1 g/cm3 |
|---|---|
| Boiling Point | 382.9ºC at 760 mmHg |
| Melting Point | 165ºC |
| Molecular Formula | C11H13BrN2O5 |
| Molecular Weight | 333.135 |
| Flash Point | 185.4ºC |
| Exact Mass | 332.000763 |
| PSA | 104.55000 |
| LogP | -0.80 |
| Index of Refraction | 1.709 |
| InChIKey | ODZBBRURCPAEIQ-PIXDULNESA-N |
| SMILES | O=c1[nH]c(=O)n(C2CC(O)C(CO)O2)cc1C=CBr |
| Water Solubility | Soluble in water and methanol. |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Safety Phrases | 24/25 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | YU7355000 |
|
Characterization of pyrimidine nucleoside phosphorylase of Mycoplasma hyorhinis: implications for the clinical efficacy of nucleoside analogues.
Biochem. J. 445(1) , 113-23, (2012) In the present paper we demonstrate that the cytostatic and antiviral activity of pyrimidine nucleoside analogues is markedly decreased by a Mycoplasma hyorhinis infection and show that the phosphorol... |
|
|
Synthesis of nucleoside-based antiviral drugs in ionic liquids.
Bioorg. Med. Chem. Lett. 18(20) , 5640-2, (2008) Nucleoside-based antiviral drugs have been synthesized using imidazolium-based ionic liquids as reaction medium. The ionic liquids were proved to be better solvents for all the nucleoside in terms of ... |
|
|
Retained sensitivity to cytotoxic pyrimidine nucleoside analogs in thymidine kinase 2 deficient human fibroblasts.
Nucleosides Nucleotides Nucleic Acids 29(1) , 1-13, (2010) Thymidine kinase 2 (TK2) is a mitochondrial deoxyribonucleoside kinase that phosphorylates several nucleoside analogs used in anti-viral and anti-cancer therapy. A fibroblast cell line with decreased ... |
| 5-[(E)-2-bromoethenyl]-2'-deoxyuridine |
| Brivudine |
| BrVDU |
| Bromovinyldeoxyuridine |
| MFCD00058585 |
| 5-[(E)-2-Bromovinyl]-2'-deoxyuridine |
| Zostrex |
| BVDU |
| (E)-5-(2-Bromovinyl)-2'-deoxyuridine |
| BVDR |